Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-induced ERP Biomarkers in Healthy Volunteers
NCT04928703Phase 1Completed
- Sponsor
- ERP Biomarker Qualification Consortium
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by ERP Biomarker Qualification Consortium. Primary endpoints: Ketamine-induced changes in Amplitude for MMN and Variability of Ketamine-induced changes on MMN. Started May 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04928703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928703.